ERNAWErnexa Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of Ernexa Therapeutics Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ERNAWEsta | $58930#5 | 0.0x#4 | 0.0x#4 | 0.1x#3 | 755.9%#1 | 68.4%#1 | -1601.2%#4 | -440.1%#6 | -1016.2%#4 | — | — | — |
| CDT | $164493#3 | 0.0x#3 | 0.0x#2 | — | — | -120.3%#6 | — | -38.0%#2 | — | — | — | — |
| BFRIW | $386161#1 | — | 0.1x#5 | 0.0x#2 | 11.7%#3 | 40.7%#2 | -27.2%#2 | -176.9%#4 | -712.4%#3 | — | — | — |
| SXTPW | $216295#2 | — | 0.1x#6 | 0.2x#4 | 65.5%#2 | 7.3%#3 | -771.6%#3 | -281.7%#5 | -163.8%#2 | 6#1 | — | — |
| SBFMW | $124463#4 | 0.0x#5 | 0.0x#3 | 0.0x#1 | 4.1%#4 | -16.4%#5 | -17.2%#1 | -21.7%#1 | -63.1%#1 | — | — | — |
| CDTTW | $5271#7 | 0.0x#2 | 0.0x#1 | — | — | -120.3%#6 | — | -38.0%#2 | — | — | — | — |
| ADTX | $7588#6 | 0.0x#1 | — | 2.4x#5 | -97.6%#5 | -6.8%#4 | -612542.2%#5 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice